Litcius/Paper detail

Phase 2 Study of the Safety and Tolerability of Maraviroc-Containing Regimens to Prevent HIV Infection in Men Who Have Sex With Men (HPTN 069/ACTG A5305)

Ian McGowan, Ian Frank, Susan H. Eshleman, Ken Ho, Robert A. Salata, Jorge Santana, Craig W. Hendrix, K. Rivet Amico, Albert Liu, Ying Qing Chen, Wairimu Chege, Alex R. Rinehart, Paul G. Richardson, Karin L. Klingman, Adriana Andrade, Raphael J. Landovitz, Mark A. Marzinke, Timothy Wilkin, Leslie M Cottle, Kenneth H. Mayer, Joanne D. Stekler, Cheryl Marcus, Alicia Young, Jason E. Farley, Manya Magnus, Roy M. Gulick, P. Andrew, James F. Rooney, Marybeth McCauley

2020eScholarship (California Digital Library)28 citationsDOIOpen Access PDF

Abstract

Maraviroc (MVC) is a candidate for human immunodeficiency virus (HIV) pre-exposure prophylaxis.

Topics & Concepts

MaravirocTolerabilityHuman immunodeficiency virus (HIV)MedicineInternal medicineVirologyPharmacologyPsychologyAdverse effectHIV/AIDS Research and InterventionsMosquito-borne diseases and control